Company / Financials
ALNYLAM PHARMACEUTICALS, INC. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$3.7B
FY2025 · +65.2% YoY
Net Income
-$18.3M
FY2025 · +93.4% YoY
Profit Margin
-0.5%
FY2025 · net income / revenue
ROE
-2.3%
FY2025 · return on equity
Total Assets
$5.0B
FY2025
Total Debt
-
FY2025
Equity
$789.2M
FY2025
ROA
-0.4%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$3.7B+65.2% YoYNet Income HistoryProfit after all expenses and taxes-$18.3M+93.4% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$677.2M+120.9% YoYOperating Income HistoryProfit from core business operations before interest and taxes$501.6M+383.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$1.2B+24.1% YoYR&D Expense HistoryResearch and development spending$1.3B+17.2% YoYInterest Expense HistoryCost of borrowing and debt obligations$121.2MIncome Tax HistoryTotal income tax expense$9.4M+109.5% YoYEPS (Basic) HistoryBasic earnings per share-$3.52+62.2% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$3.52+62.2% YoY